MYSTERIOUS: Sandoz - What They Never Told You

Consumers Who Bought Certain Generics From 2009 to 2019 Can Claim Share of $400 Million Sandoz Settlement

Sandoz will pay $400 million to settle state claims that it helped inflate generic drug prices. Here is who may qualify and the March 8, 2027, deadline.

Medical Daily · Oct 5

Sandoz bets big on biosimilars, aims to double group sales by 2035

Sandoz plans to more than double annual net sales by 2035, with biosimilars leading growth. The company will expand its biosimilar portfolio to 100 drugs by 2040. Sandoz targets mid-to-high single-digit sales growth from 2025 to 2030. Its net sales targets exclude potential contributions from generic GLP-1 drugs. Sandoz will…

The Economic Times · Sep 8

Global Market: European shares slip as oil surge fuels inflation fears; Novartis plunges

European shares slipped as surging oil prices raised inflation concerns amid escalating Middle East tensions and threats to Gulf energy infrastructure. The STOXX 600 fell 0.2%, while Germany and France declined. Novartis plunged after a second drug trial setback, whereas Sandoz gained on ambitious long-term growth targets. Investors monitored energy…

The Economic Times · Sep 8

Americans would suffer most if Trump imposes pharma tariffs, sector warns

Industry says levies would hit supply chains, making medicines potentially unaffordable for some US patients

The Guardian - UK · May 5, 2025

MS patients suffer side-effects after NHS England switches to cheaper drug

Scores of people experience complications after change from Tysabri to Tyruko as part of NHS drive to save money

The Guardian - UK · Feb 24, 2025

UK grocery inflation picks up to 2.3%; unemployment rises while regular wage growth slows – as it happened

Consumers started their Christmas shopping early, Kantar says; UK jobless rate rises to 4.3% while wage growth excluding bonuses is at a two-year low

The Guardian - UK · Nov 12, 2024

3 Pharma Stocks With Potential to Outperform Pfizer Inc. (PFE) in October

Pfizer (PFE) is grappling with financial difficulties and declining performance. Yet, with growing pharmaceutical demand and industry advancements, robust pharma stocks Zoetis (ZTS), Horizon Therapeutics (HZNP), and Novartis (NVS) appear as more promising buys this month. Read on.

StockNews.com · Oct 5, 2023

3 Pharma Stocks Surpassing Johnson & Johnson (JNJ)

The pharmaceutical sector is anticipated to thrive as demand grows and technology advances. While Johnson & Johnson (JNJ) receives much attention from investors, I believe Horizon Therapeutics Public Limited (HZNP), Dr. Reddy’s Laboratories (RDY), and Novartis (NVS) are better investments right now. Read on.

StockNews.com · Sep 12, 2023

Top 3 Pharma Stocks to Boost Your Portfolio

As the global population ages and faces the increasing toll of chronic diseases, the pharmaceutical industry is expected to step up to meet people’s healthcare needs. Against this backdrop, pharma companies like Novo Nordisk (NVO), AbbVie (ABBV), and Novartis (NVS) could boost your portfolio. Read on….

StockNews.com · Sep 4, 2023

3 Pharma Stocks With Promising Pipelines

The pharma industry is anticipated to stay buoyed in the years to come with consistent medical breakthroughs and rising need to serve an aging population. Therefore, pharma stocks Johnson & Johnson (JNJ), Novartis AG (NVS), and Dr. Reddy's Laboratories (RDY), which possess promising pipelines, could be wise portfolio additions now.…

StockNews.com · Aug 25, 2023